Liquid Biopsy Market Cancer Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Liquid Biopsy Market
Liquid Biopsy Market: Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), End User (Reference Laboratory, Research Centers) & By Region-Forecast (2016-2021)
Report Code : HCR 0292
Published: 14 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Liquid biopsy is an advanced cancer diagnostic test carried out using biofluids such as blood, CSF, plasma and urine for cancer detection. Liquid biopsy test can be used to detect cancer in early stages. Liquid biopsy is a non-invasive diagnostic test which uses circulating nucleic acids, circulating tumour cells (CTC) and exosomes as a biomarker for diagnosis of cancer. Aforementioned biomarkers are released into different body fluids by cancer cells into cancerous human body. Liquid biopsy test requires blood, urine and cerebral spinal fluid (CSF) samples for diagnosis of various cancers. Among all samples, blood sample is widely used for diagnosis of various cancers such as lung cancer, breast cancer and leukemia. Urine and CSF samples are used for diagnosis of prostate cancer and brain cancer respectively. Globally increasing cancer awareness and incidences is expected to drive the demand for liquid biopsy during the period of study.

Liquid Biopsy Market

Geographically North America dominated global liquid biopsy market, with approximately half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region. Among all the procedures, oncology procedures has the highest market share in global liquid biopsy market due to higher prevalence of cancer patients.

This report identifies the global liquid biopsy market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global liquid biopsy market.

This report segments global liquid biopsy market on the basis of cancer type, Circulating Biomakers , end-user, and regional market as follows:
  • Liquid Biopsy Market, By cancer type: Lung, Breast, Colorectal, Prostate, Liver
  • The report has focused study on liquid biopsy market on basis of Circulating biomarker such as: Tumor Cells, Circulating Tumor DNA and other,
  • The report has focused study on liquid biopsy market on basis of End User such as: Reference Laboratory, Research Centers
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the liquid biopsy market. Some of the major companies’ profiles in detail are as follows:
  • F. Hoffmann-La Roche AG
  • Bio-Rad Laboratories Inc.
  • Myriad Genetics
  • Janssen Diagnostics, LLC.
  • Tr0vagene Inc.
1. Liquid Biopsy Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Liquid Biopsy Market– Market Forces
   4.1. Drivers
      4.1.1. Increasing cases of new cancer patients
      4.1.2. Benefits of Liquid Biopsy Over Surgical Biopsy
   4.2. Restraints
      4.2.1. Low Sensitivity and Specificity
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Liquid Biopsy Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Liquid Biopsy Market, By Cancer Type
   6.1. Lung Cancer
   6.2. Breast Cancer
   6.3. Colorectal Cancer
   6.4. Prostate Cancer
   6.5. Liver Cancer
   6.6. Other Cancers
7. Liquid Biopsy Market, By Circulating Biomarker
   7.1. Circulating Tumor Cells
   7.2. Extracellular Vesicles
   7.3. Circulating Tumor DNA (CTDNA)
   7.4. Other Biomarkers
8. Liquid Biopsy Market, By End-User
   8.1. Reference Laboratory,
   8.2. Research Centers
9. Liquid Biopsy Market, By Geography
   9.1. Europe
      9.1.1. Germany
      9.1.2. France
      9.1.3. Italy
      9.1.4. Spain
      9.1.5. Russia
      9.1.6. U.K.
      9.1.7. Rest of Europe
   9.2. Asia Pacific
      9.2.1. China
      9.2.2. India
      9.2.3. Japan
      9.2.4. South Korea
      9.2.5. Rest of Asia-Pacific
   9.3. North America
      9.3.1. U.S.
      9.3.2. Canada
      9.3.3. Mexico
   9.4. Rest of the World (RoW)
      9.4.1. Brazil
      9.4.2. Rest of RoW
10. Liquid Biopsy – Market Entropy
   10.1. Expansion
   10.2. Technological Developments
   10.3. Merger & Acquisitions, and Joint Ventures
   10.4. Supply- Contract
11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   11.1. Biocept, Inc.
   11.2. Qiagen
   11.3. F. Hoffmann-La Roche AG
   11.4. Bio-Rad Laboratories Inc.
   11.5. Myriad Genetics
   11.6. Janssen Diagnostics, LLC.
   11.7. Tr0vagene Inc.
   11.8. Guardant Health Inc.
   11.9. Fraunhofer-Gesellschaft
   11.10. MDX Health SA
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Bibliography
   12.5. Compilation of Expert Insights
   12.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll